First battle of the 'Ozempic' pill: Lilly's tablet outperforms Novo Nordisk's
Lilly's anti-obesity pill, orforglipron, shows better results than Novo Nordisk's semaglutide in controlling blood sugar and weight for type 2 diabetes patients, despite higher discontinuation rates due to side effects.
New oral GLP-1 reduces more glucose and weight than semaglutide in phase 3 study; Orforgliprona increases weight loss by 73%
The experimental drug orforgliprona demonstrated greater glucose control and weight loss compared to oral semaglutide in a phase 3 study for type 2 diabetes treatment.
Pharmaceutical company Dr. Reddy's prepares to launch a cheap generic Ozempic in India in March
Indian pharmaceutical company Dr. Reddy’s Laboratories is set to launch a generic version of the diabetes drug Ozempic, named Obeda, in March 2026 following the expiration of the semaglutide patent.
End of Ozempic patent could reduce price by up to 35%, says laboratory wanting to make generic
The expiration of the semaglutide patent in March is expected to lead to a price reduction of up to 35% for Ozempic, according to pharmaceutical company EMS, which is interested in producing a generic version.
Weight loss jabs could be banned by next Olympics
The World Anti-Doping Agency is considering banning weight loss injections, such as those containing Semaglutide, in the next Summer Olympics due to potential performance enhancement and health risks.
Anvisa is set to decide next week on national versions of Ozempic
Brazil's National Health Surveillance Agency (Anvisa) is expected to announce its decision regarding the registration of national versions of semaglutide-based pens, essential for diabetes treatment, next week.
Doctor warns: weight loss drugs are only part of a comprehensive treatment
A Lithuanian doctor highlights the risks of using weight loss medications like semaglutide without proper medical guidance, emphasizing that they should be part of a broader treatment plan.
Anvisa says it will comment in the coming weeks on the registration of two competitors to Ozempic
Anvisa, Brazil's health regulatory agency, is expected to make a decision in the coming weeks regarding the approval of two competitors to Ozempic and Wegovy, as the substance semaglutide loses its patent.
Does it work or not? Expert reveals the risks of Ozempic injections for weight loss
An expert discusses the risks associated with Ozempic injections, initially developed for diabetes treatment, as a weight loss solution.
What diseases can the use of Ozempic trigger? Here’s what you need to know before starting treatment
The article discusses the potential health risks associated with Ozempic, a drug often misused for weight loss.
Novo Nordisk: Frenzied rally after the withdrawal of a weight loss drug
Novo Nordisk's stock surged approximately 8% following Hims & Hers's decision to withdraw a low-cost weight loss pill similar to Wegovy amid legal threats from both Novo Nordisk and the FDA.
Mounjaro Rotation' trivializes the use of medications, say specialists
Experts warn that restaurant initiatives offering reduced portions for users of the medication semaglutide, branded as 'Mounjaro Rotation,' may trivialize its use and alter dining dynamics.
How the drugs that will revolutionize obesity treatment work
Semaglutide by Novo Nordisk is the first drug approved for obesity treatment that achieves weight loss comparable to bariatric surgery, while Eli Lilly's tirzepatide is expected to gain approval soon after showing efficacy and safety in clinical trials.
The 'miracle pill' against obesity achieves a new victory: it protects the heart
A new study reveals that oral semaglutide, initially designed for diabetes management, shows potential benefits for heart failure patients as well.
Anvisa approves indication of Ozempic and Wegovy to reduce the risk of heart attack and stroke
Anvisa has approved the use of semaglutide for adults with established cardiovascular disease or obesity to reduce the risk of heart attack and stroke.
Anvisa approves the use of semaglutide for reducing cardiovascular risk
Brazil's National Health Surveillance Agency (Anvisa) has approved semaglutide for reducing the risk of cardiovascular events, a drug popularized for weight loss efficacy.
New alert for everyone taking semaglutide and tirzepatide weight loss jabs
A study reveals that individuals using semaglutide and tirzepatide for weight loss regain weight much faster after stopping the medication compared to traditional dieters, highlighting the need for ongoing support.